WebAug 6, 2024 · BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with ... WebBioInvent International AB is a biopharmaceutical company. It develops a pipeline of innovative immuno-oncology therapies for cancer therapy based on its unique F.I.R.S.T technology platform and n-CoDeR antibody library. The products under its pipeline are BI-1206, BT-001, BI-1808, and BI-1910. Its geographical segments are Sweden, Europe ...
BioInvent International AB: Interim report January-September 2024
WebAug 26, 2024 · BioInvent received IND approval for Phase 1/2a trial of anti-TNFR2 antibody BI-1808. ... Cecilia Hofvander, Investor Relations +46 (0)46 286 85 50 [email protected] ... WebFeb 23, 2024 · BioInvent announced the appointment of Cecilia Hofvander as Senior Director Investor Relations, a new position at BioInvent starting mid-February 2024. Events after the reporting period bishop rex
BioInvent strengthens Investor Relations - prnewswire.com
WebApr 7, 2024 · Apr 07, 2024, 02:43 ET. LUND, Sweden, April 7, 2024 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration ... WebOct 25, 2024 · Cecilia Hofvander, Senior Director Investor Relations Phone: +46 (0) 46 286 85 50 Email: [email protected]. BioInvent International AB (publ) Co. Reg. No. Org nr: 556537-7263 Visiting address: Ideongatan 1 Mailing address: 223 70 LUND Phone: +46 (0) 46 286 85 50 www.bioinvent.com Web--SEK +/-+/-Opening price: Bid: Ask: High: Low: Volume: Turnover: Updated dark sacred night by michael connelly kindle